Loading
NASDAQHealthcareMedical - Diagnostics & Research
Latest quote
$4.20
+$0.22 · +5.53%
OncoCyte Corporation functions as a molecular diagnostics firm specializing in the research, development, and market introduction of distinctive, laboratory-developed tests aimed at cancer identification. Its operations span both the United States and international territories. The company's key offerings include DetermaRx, a molecular diagnostic tool tailored for detecting early-stage adenocarcinoma of the lung, and DetermaIO, a proprietary gene expression analysis. Additionally, OncoCyte provides a range of expert services, such as biomarker discovery, assay design and refinement, and clinical trial assistance, which encompass offering various biomarker tests to pharmaceutical partners. A strategic partnership with Life Technologies Corporation focuses on the collaborative development and commercialization of the Oncomine Comprehensive Assay Plus and Determa IO assay, intended for integration with the Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was founded in 2009 and maintains its principal office in Irvine, California.
Previous close
$4.20
+$0.22 · +5.53%
Regular session · ET · Market data may be delayed.
OncoCyte Corporation functions as a molecular diagnostics firm specializing in the research, development, and market introduction of distinctive, laboratory-developed tests aimed at cancer identification. Its operations span both the United States and international territories. The company's key offerings include DetermaRx, a molecular diagnostic tool tailored for detecting early-stage adenocarcinoma of the lung, and DetermaIO, a proprietary gene expression analysis. Additionally, OncoCyte provides a range of expert services, such as biomarker discovery, assay design and refinement, and clinical trial assistance, which encompass offering various biomarker tests to pharmaceutical partners. A strategic partnership with Life Technologies Corporation focuses on the collaborative development and commercialization of the Oncomine Comprehensive Assay Plus and Determa IO assay, intended for integration with the Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was founded in 2009 and maintains its principal office in Irvine, California.
Day range
Current $4.20
52-week range
Current $4.20
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
38
Expensive
Sentiment
44
Mixed
Risk
71
High Risk
Momentum
31
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
OncoCyte Corporation functions as a molecular diagnostics firm specializing in the research, development, and market introduction of distinctive, laboratory-developed tests aimed at cancer identification. Its operations span both the United States and international territories. The company's key offerings include DetermaRx, a molecular diagnostic tool tailored for detecting early-stage adenocarcinoma of the lung, and DetermaIO, a proprietary gene expression analysis. Additionally, OncoCyte provides a range of expert services, such as biomarker discovery, assay design and refinement, and clinical trial assistance, which encompass offering various biomarker tests to pharmaceutical partners. A strategic partnership with Life Technologies Corporation focuses on the collaborative development and commercialization of the Oncomine Comprehensive Assay Plus and Determa IO assay, intended for integration with the Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was founded in 2009 and maintains its principal office in Irvine, California.
Day range
Current $4.20
52-week range
Current $4.20
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 4.06M USD | 1.88M USD | 1.5M USD | 958K USD | 2.2M USD |
| Cost of goods sold | 3.87M USD | 1.14M USD | 1.09M USD | 976K USD | 778K USD |
| Gross profit | 190K USD | 740K USD | 413K USD | −18K USD | 1.42M USD |
| Research and development | 15.9M USD | 9.84M USD | 9.29M USD | 7.3M USD | 5.04M USD |
| Selling, general, and administrative | 16.98M USD | 13.79M USD | 13.29M USD | 21.53M USD | 20.39M USD |
| Operating expenses | 30.77M USD | 61.78M USD | 25.55M USD | 17.98M USD | 55.15M USD |
| Interest expense | 109K USD | 84K USD | 52K USD | 83K USD | 209K USD |
| Depreciation and amortization | 2.2M USD | 1.56M USD | 1.68M USD | 5.22M USD | 4.21M USD |
| Operating income | −30.58M USD | −61.04M USD | −25.14M USD | −18M USD | −53.73M USD |
| Net income | −50.22M USD | −60.66M USD | −27.78M USD | −72.9M USD | −64.1M USD |
Company facts updated Sep 13, 2026.
Third-party consensus; not a GoAI recommendation.
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI
Vanguard Extended Market ETFVXF
iShares Micro-Cap ETFIWCAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
